File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
  • Find via Find It@HKUL
Supplementary

Conference Paper: Serologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance

TitleSerologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearance
Authors
KeywordsMedical sciences
Gastroenterology
Issue Date2012
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep
Citation
The 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012, v. 56 suppl. 2 , p. S214-S215, abstract no. 541 How to Cite?
Abstract
BACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance after nucleoside analogue (NA) therapy is an uncommon event. The serologic and virologic kinetics after HBsAg seroclearance and cessation of therapy have not been previously described. METHODS: Between December 1999 and June 2011, 42 (73.9% male) patients developed HBsAg seroclearance after NA therapy. Serum HBV DNA and HBsAg levels were determined at baseline, time of HBsAg loss and after cessation of therapy. They were measured by Cobas Taqman assay (lower limit of detection 20 IU/mL) and Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL) respectively. RESULTS: HBsAg seroclearance occurred in a median duration of 48.8 (range: 4.8 to 189.0) months after therapy commencement. Twenty-nine (69.0%), 10 (23.8%), 2 (4.8%) and 1 (2.4%) patients were on lamivudine, entecavir, lamivudine plus adefovir and telbivudine respectively. At the time of writing, 22 patients (52.4%) developed anti-HBs. Seven patients (16.7%, 6 on lamivudine, 1 on entecavir) stopped therapy after a median treatment duration of 39.9 (range 12.8 to 112.4) months, before HBsAg seroclearance which occurred after at a median time of 36.4 (range 17.2 to 94.9) months. Of the 35 patients who continued taking NA till HBsAg seroclearance, 17 (48.6%) stopped therapy 17.9 (range 1.4 to 87.6) months after HBsAg seroclearance. Among patients with therapy ceased for more than 6 months (n = 14, median time 21.9 months, range 6.4 to 53.3 months), 13 (92.6%) maintained an undetectable level of serum HBV DNA and HBsAg. One patient (7.1%) developed HBsAg seroreversion and hepatitic flare 29 months after cessation of lamivudine. She achieved HBsAg seroclearance and viral suppression to undetectable levels again at 4 and 7 months respectively after retreatment of entecavir. There were no cases of HBsAg seroreversion among the 18 patients (51.4%) maintaining therapy 15.9 (range 3.7 to 58.8) months after HBsAg seroclearance. CONCLUSION: Majority of CHB patients who stopped treatment after CHB seroclearance maintained virologic and serologic stability.
DescriptionThis journal suupl. contain Abstracts of the 2012 International Liver Congress™ and the 47th EASL Annual Meeting
Persistent Identifierhttp://hdl.handle.net/10722/165462
ISSN
2013 Impact Factor: 10.401

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKen_US
dc.contributor.authorWong, DKHen_US
dc.contributor.authorFung, Jen_US
dc.contributor.authorYuen, JCHen_US
dc.contributor.authorHung, IFNen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorYuen, RMFen_US
dc.date.accessioned2012-09-20T08:18:24Z-
dc.date.available2012-09-20T08:18:24Z-
dc.date.issued2012en_US
dc.identifier.citationThe 47th Annual Meeting of the European Association for the Study of the Liver (EASL 2012), Barcelona, Spain, 18-22 April 2012. In Journal of Hepatology, 2012, v. 56 suppl. 2 , p. S214-S215, abstract no. 541en_US
dc.identifier.issn0168-8278-
dc.identifier.urihttp://hdl.handle.net/10722/165462-
dc.descriptionThis journal suupl. contain Abstracts of the 2012 International Liver Congress™ and the 47th EASL Annual Meeting-
dc.descriptionPoster no. 541-
dc.description.abstractBACKGROUND: Hepatitis B surface antigen (HBsAg) seroclearance after nucleoside analogue (NA) therapy is an uncommon event. The serologic and virologic kinetics after HBsAg seroclearance and cessation of therapy have not been previously described. METHODS: Between December 1999 and June 2011, 42 (73.9% male) patients developed HBsAg seroclearance after NA therapy. Serum HBV DNA and HBsAg levels were determined at baseline, time of HBsAg loss and after cessation of therapy. They were measured by Cobas Taqman assay (lower limit of detection 20 IU/mL) and Roche Elecsys HBsAg II assay (lower limit of detection 0.05 IU/mL) respectively. RESULTS: HBsAg seroclearance occurred in a median duration of 48.8 (range: 4.8 to 189.0) months after therapy commencement. Twenty-nine (69.0%), 10 (23.8%), 2 (4.8%) and 1 (2.4%) patients were on lamivudine, entecavir, lamivudine plus adefovir and telbivudine respectively. At the time of writing, 22 patients (52.4%) developed anti-HBs. Seven patients (16.7%, 6 on lamivudine, 1 on entecavir) stopped therapy after a median treatment duration of 39.9 (range 12.8 to 112.4) months, before HBsAg seroclearance which occurred after at a median time of 36.4 (range 17.2 to 94.9) months. Of the 35 patients who continued taking NA till HBsAg seroclearance, 17 (48.6%) stopped therapy 17.9 (range 1.4 to 87.6) months after HBsAg seroclearance. Among patients with therapy ceased for more than 6 months (n = 14, median time 21.9 months, range 6.4 to 53.3 months), 13 (92.6%) maintained an undetectable level of serum HBV DNA and HBsAg. One patient (7.1%) developed HBsAg seroreversion and hepatitic flare 29 months after cessation of lamivudine. She achieved HBsAg seroclearance and viral suppression to undetectable levels again at 4 and 7 months respectively after retreatment of entecavir. There were no cases of HBsAg seroreversion among the 18 patients (51.4%) maintaining therapy 15.9 (range 3.7 to 58.8) months after HBsAg seroclearance. CONCLUSION: Majority of CHB patients who stopped treatment after CHB seroclearance maintained virologic and serologic stability.-
dc.languageengen_US
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jhep-
dc.relation.ispartofJournal of Hepatologyen_US
dc.subjectMedical sciences-
dc.subjectGastroenterology-
dc.titleSerologic and virologic kinetics after stopping nucleoside analogue therapy in hepatitis B surface antigen (HBSAG) seroclearanceen_US
dc.typeConference_Paperen_US
dc.identifier.emailSeto, WK: wkseto2@hku.hken_US
dc.identifier.emailWong, DKH: danywong@hku.hken_US
dc.identifier.emailFung, J: jfung@hkucc.hku.hken_US
dc.identifier.emailYuen, JCH: jchyuen@hkucc.hku.hken_US
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hken_US
dc.identifier.emailLai, CL: hrmelcl@hku.hken_US
dc.identifier.emailYuen, RMF: mfyuen@hku.hken_US
dc.identifier.authoritySeto, WK=rp01659en_US
dc.identifier.authorityWong, DKH=rp00492en_US
dc.identifier.authorityFung, J=rp00518en_US
dc.identifier.authorityHung, IFN=rp00508en_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.identifier.authorityYuen, RMF=rp00479en_US
dc.identifier.hkuros211098en_US
dc.identifier.volume56en_US
dc.identifier.issuesuppl. 2en_US
dc.identifier.spageS214en_US
dc.identifier.epageS215en_US
dc.publisher.placeNetherlands-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats